🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Sheffield
Clinical trial register · United Kingdom · industry-sponsored

Clinical Trials in Sheffield

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2846 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 19 Sep 2026, 04:26 UTC
2846
Studies in scope
industry-sponsored, all four open statuses
1377
Recruiting now
open to new participants
539
Lead sponsors
across recruiting studies
Top sites
London 2003 Manchester 674 Birmingham 469 Glasgow 437 Cambridge 416
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Eli Lilly and Company13 Novartis Pharmaceuticals11 Janssen Research & Development, LLC10 AstraZeneca10 Novo Nordisk A/S8
Site city
London2003 Manchester674 Birmingham469 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
214 of 2846 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203Alzheimer's Disease
Bristol-Myers Squibb
Phase 3
586
Manchester, London, Edinburgh, Oxford, Birmingham, Leeds, Motherwell, Sheffield
2025-07-21
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
NCT07011745Alzheimer's Disease
Bristol-Myers Squibb
Phase 3
426
Preston, Chertsey, Cambridge, London, Motherwell, Redruth, Sheffield, Stafford
2025-07-16
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
Takeda
Phase 3
347
London, Birmingham, Canterbury, Hull, Leicester, Nottingham, Preston, Sheffield
2025-07-15
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605Atopic Dermatitis
Galderma R&D
Observational
1,000
London, Southampton, Watford, Kings Lynn, Harrogate, Sheffield, Birmingham, Leeds
2025-07-14
Active, closed
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
NCT07003919Allergy, Peanut Allergy
DBV Technologies
Phase 3
480
Glasgow, Leicester, London, Manchester, Sheffield, Southampton
2025-06-24
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
400
Sheffield, Leeds, London, Swansea
2025-06-23
Recruiting
A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA Trial
NCT06786234Essential Thrombocythaemia
Step Pharma, SAS
Phase 2
50
Sheffield, Cardiff, London, Oxford, Southampton
2025-06-18
Active, closed
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618Atopic Dermatitis
Incyte Corporation
Phase 3
159
Glasgow, London, Metropolitan Borough of Wirral, Nottingham, Sheffield, Walsall
2025-06-17
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
Avidity Biosciences, Inc.
Phase 3
200
London, Newcastle upon Tyne, Sheffield
2025-06-10
Recruiting
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
NCT06953583Friedreich Ataxia
Biogen
Phase 3
255
London, Oxford, Sheffield
2025-06-09
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
Stoke Therapeutics, Inc
Phase 3
170
Glasgow, London, Sheffield
2025-06-04
Recruiting
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06963021Major Depressive Disorder
Neurocrine Biosciences
Phase 3
200
London, Salford, Sheffield, Southampton
2025-05-30
Recruiting
Surgical vs Transcatheter Aortic Valve Replacement in YOUNG Patients
NCT06861361Symptomatic Severe Aortic Stenosis
Ceric Sàrl
Not applicable
1,180
Belfast, Brighton, Cambridge, Cottingham, Coventry, London, Newcastle upon Tyne, Sheffield
2025-05-15
Recruiting
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06935357Immunoglobulin A Nephropathy (IgAN)
Biogen
Phase 3
454
London, Preston, Leicester, Sheffield, Stoke-on-Trent
2025-05-08
Active, closed
Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis
NCT06799247Myasthaenia Gravis
Cartesian Therapeutics
Phase 3
128
Birmingham, Sheffield
2025-05-06
By invitation
A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I
NCT06926621Myotonic Dystrophy Type 1 (DM1)
Vertex Pharmaceuticals Incorporated
Phase 2
44
Glasgow, London, Sheffield
2025-04-28
By invitation
An Interventional Study of Infigratinib in Children With Hypochondroplasia
NCT06873035Hypochondroplasia
QED Therapeutics, a BridgeBio company
Phase 2/3
24
Manchester, Sheffield, Glasgow
2025-04-22
Active, closed
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
NCT06704269Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 1/2
15
Sheffield, London
2025-04-22
Recruiting
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869Insomnia Disorder
Vanda Pharmaceuticals
Phase 3
420
Great Yarmouth, Leicester, Liverpool, London, Sheffield
2025-04-21
Recruiting
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NCT06966401Major Depressive Disorder
Neurocrine Biosciences
Phase 3
850
Southampton, Sheffield, London, Manchester
2025-04-16
Recruiting
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248Multiple Sclerosis
ModernaTX, Inc.
Phase 2
180
Bristol, Cardiff, Edinburgh, Glasgow, London, Newcastle upon Tyne, Sheffield
2025-04-16
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Blackpool, Colchester, Essex, Edinburgh, Harlow, London, Northwood, Oxford, Sheffield
2025-04-09
Recruiting
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
NCT06846554Pulmonary Arterial Hypertension
Apollo Therapeutics Ltd
Phase 2
48
London, Bath, Cambridge, Clydebank, Sheffield
2025-04-09
Recruiting
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
NCT06819007Ovarian Cancer
Daiichi Sankyo
Phase 3
582
Cambridge, London, Manchester, Oxford, Sheffield
2025-03-19
Recruiting
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
NCT06615479Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3
440
Cambridge, London, Oxford, Manchester, Newcastle upon Tyne, Sheffield
2025-03-12
Rows per page Showing 51–75 of 214
Previous 1 2 3 4 5 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-uk/city/sheffield

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.